Page 365«..1020..364365366367..370380..»

Stem Cell Therapy Market Overview by Advance Technology, Future Outlook 2028 Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and…

Posted: July 3, 2022 at 2:02 am

The global Mobile Cardiac Telemetry Systems Market research report gives a comprehensive analysis of market size, market trends, and market growth prospects. This report also provides extensive information on the technology expenditure for the forecast period, which gives a unique view of the global Mobile Cardiac Telemetry Systems Market across multiple segments. The global Mobile Cardiac Telemetry Systems market report also helps consumers recognize market opportunities and challenges. This report includes the most current Mobile Cardiac Telemetry Systems market forecast research over the expected period. The global Mobile Cardiac Telemetry Systems market report provides extensive information on technological developments and market growth prospects based on regional landscapes. The Mobile Cardiac Telemetry Systems Market Report is also designed using advanced methodologies and includes a detailed analysis of the Mobile Cardiac Telemetry Systems marketplaces sales and providers.

Free Sample Report + All Related Graphs & Charts @ https://www.adroitmarketresearch.com/contacts/request-sample/1746?utm_source=Sujag01

Leading players of Mobile Cardiac Telemetry Systems Market including:

BioTelemetry Inc., Biotricity Inc., ScottCare, Welch Allyn, Medicomp Inc., Applied Cardiac Systems Inc., Preventice Solutions, iRhythm Technologies, Inc., Telerhythmics LLC

In addition to this, the report by Adroit Market Research has been designed through the complete surveys, primary research interviews, as well as observations, and secondary research. Moreover, the Mobile Cardiac Telemetry Systems market report introduced the market through several factors such as classifications, definitions, market overview, product specifications, cost structures, manufacturing processes, raw materials, and applications. Moreover, the study offers a complete analysis of the market size, segmentation, and market share. Additionally, the Mobile Cardiac Telemetry Systems report contains market dynamics such as market restraints, growth drivers, opportunities, service providers, stakeholders, investors, key market players, profile assessment, and challenges of the global market.

Further to this, the Mobile Cardiac Telemetry Systems market report by Adroit Market Research holistically touches upon well-orchestrated data sources and insightful factors about multiple manufacturers and market honchos working extensively in the Mobile Cardiac Telemetry Systems market. This report also entails supply chain nuances, financial data analysis, products & services records, core developments, as well as elaborate description on acquisitions & mergers, current & future growth probabilities trends, as well as advances, inclusive of technological sophistication, that carefully craft market players footprint in the global Mobile Cardiac Telemetry Systems market.

The market segmentation information in the research report is a combination of primary and secondary research methods. The report includes both a quantitative as well as qualitative analysis of target market evaluations over the forecasted period to show the economic potential of the global target market. The global Mobile Cardiac Telemetry Systems industry is covered in this report, which includes current and prospective market trends. This will help to determine the potential market investment for the Mobile Cardiac Telemetry Systems industry. The research report also includes an industry analysis and forecasts for the registered forecast period. In addition, the Mobile Cardiac Telemetry Systems Market Study provides comprehensive data about the opportunities, key driver, and restraining factor with the contact analysis.

Mobile Cardiac Telemetry Systems market Segmentation by Type:

NA

Mobile Cardiac Telemetry Systems market Segmentation by Application:

By Application (Lead-Based, Patch-Based) End Use (Hospitals, Cardiac Centers, Others)

The Mobile Cardiac Telemetry Systems Market Reports Key Highlights:

The Mobile Cardiac Telemetry Systems global market report provides a comprehensive qualitative and quantitative analysis that will provide insight into the industry. This Mobile Cardiac Telemetry Systems market insight includes data from influential participants such as marketers, business experts and investors. The Mobile Cardiac Telemetry Systems market reports objective is to provide a comprehensive perspective from all stakeholders for young marketers and entrepreneurs. Trends and drivers are discussed in the Mobile Cardiac Telemetry Systems Market Report The global Mobile Cardiac Telemetry Systems market report provides an overview of the global competitive environment. It provides information about the market, its share and revenue. The Mobile Cardiac Telemetry Systems Market Report identifies the major growth regions, with Asia Pacific leading during the forecast period.

Table of Content:

Chapter 1. Research ObjectiveChapter 2. Executive SummaryChapter 3. Strategic AnalysisChapter 4. Mobile Cardiac Telemetry Systems Market DynamicsChapter 5. Segmentation & StatisticsChapter 6. Market Use case studiesChapter 7. KOL RecommendationsChapter 8. Investment LandscapeChapter 9. Competitive IntelligenceChapter 10. Company ProfilesChapter 11. AppendixContinued

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1746?utm_source=Sujag01

ABOUT US:

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

CONTACT US:

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1.210.667.2421/ +91 9665341414

Read the rest here:
Stem Cell Therapy Market Overview by Advance Technology, Future Outlook 2028 Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and...

Posted in Cell Therapy | Comments Off on Stem Cell Therapy Market Overview by Advance Technology, Future Outlook 2028 Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and…

Cell Therapy And Tissue Engineering Market Size, Scope and Forecast | BioCardia Inc., Betalin Therapeutics Ltd., MEDIPOST Co. Ltd., MaxCyte Inc.,…

Posted: July 3, 2022 at 2:02 am

New Jersey, United States This Cell Therapy And Tissue Engineering Market research examines the state and future prospects of the Cell Therapy And Tissue Engineering market from the perspectives of competitors, regions, products, and end Applications/industries. The Worldwide Cell Therapy And Tissue Engineering market is segmented by product and Application/end industries in this analysis, which also analyses the different players in the global and key regions.

The analysis for the Cell Therapy And Tissue Engineering market is included in this report in its entirety. The in-depth secondary research, primary interviews, and internal expert reviews went into the Cell Therapy And Tissue Engineering reports market estimates. These market estimates were taken into account by researching the effects of different social, political, and economic aspects, as well as the present market dynamics, on the growth of the Cell Therapy And Tissue Engineering market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=12301

Key Players Mentioned in the Cell Therapy And Tissue Engineering Market Research Report:

BioCardia Inc., Betalin Therapeutics Ltd., MEDIPOST Co. Ltd., MaxCyte Inc., BioReliance Corporation

The Porters Five Forces analysis, which explains the five forces: customers bargaining power, distributors bargaining power, the threat of substitute products, and degree of competition in the Cell Therapy And Tissue Engineering Market, is included in the report along with the market overview, which includes the market dynamics. It describes the different players who make up the market ecosystem, including system integrators, middlemen, and end-users. The competitive environment of the Cell Therapy And Tissue Engineering marketis another major topic of the report. For enhanced decision-making, the research also provides in-depth details regarding the COVID-19 scenario and its influence on the market.

Cell Therapy And Tissue EngineeringMarket Segmentation:

Cell Therapy and Tissue Engineering Market, By Type

Cell Therapy Tissue Engineering Others

Cell Therapy and Tissue Engineering Market, By Application

Cell Defects Genetic Diseases Tissue Malignancy Neurodegenerative Disease Others

Inquire for a Discount on this Premium Report@ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=12301

Cell Therapy And Tissue Engineering Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Cell Therapy And Tissue Engineering market?

2. How will the Cell Therapy And Tissue Engineering market change in the next five years?

3. Which product and application will take a lions share of the Cell Therapy And Tissue Engineering market?

4. What are the drivers and restraints of the Cell Therapy And Tissue Engineering market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Cell Therapy And Tissue Engineering market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/cell-therapy-and-tissue-engineering-market/

Visualize Cell Therapy And Tissue Engineering Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Cell Therapy And Tissue Engineering Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Read the original:
Cell Therapy And Tissue Engineering Market Size, Scope and Forecast | BioCardia Inc., Betalin Therapeutics Ltd., MEDIPOST Co. Ltd., MaxCyte Inc.,...

Posted in Cell Therapy | Comments Off on Cell Therapy And Tissue Engineering Market Size, Scope and Forecast | BioCardia Inc., Betalin Therapeutics Ltd., MEDIPOST Co. Ltd., MaxCyte Inc.,…

Leukapheresis Market Dynamic Demand and Drives with Forecast to 2031 – Digital Journal

Posted: July 3, 2022 at 2:02 am

Leukapheresis is a laboratory procedure to separate white blood cells from a sample of blood which can occur with chronic lymphocytic leukemia (CLL). Leukapheresis is a good treatment option for patients who have very high white blood cell count or to obtain white blood cells for later transplant to treat decrease in white blood cells during chemotherapy. It also helps fightingprostate cancerand other form of cancers.

Earlier, leukapheresis was designed for palliative treatment for leukemia with only limited efficacy. But later as this technique was used for treatment modality for hyperleukocytic acute myeloid leukemia, and now it is also used to collect granulocytes to transfuse into neutropenic patients with bacterial or fungal infections, the growth of adoption of this technique is expected to increase.

GET A BROCHURE OF THE REPORT

How Leukapheresis is important for CAR or Adaptive Cell Therapy Manufacturing?

Chimeric antigen receptor(CAR) T cell therapymay be offered to people when their cancer comes back. Leukapheresis is the first step in this treatment. Research is going on for this treatment. Researchers want to collect T cells from people who may become eligible for a CAR T-cell study in the future. Leukapheresis is an essential step for CAR therapy or other adaptive cellular therapy products. The procedure is required to develop a streamlined process where patients have to undergo apheresis for development of a CAR cell or other adoptive cell therapy product. Once patient meets the eligibility conditions for one of the NCI CAR clinical cell therapy trials, they will undergo leukapheresis estimated by recipient weight and target cell harvest dose in Department of Transfusion Medicine (DTM). Therefore, need for leukapheresis in CAR therapy is a major factor for the boost in its adoption.

Prevalence of Leukemia Is projected to Boost the Treatment

Cases of leukemia have been increasing significantly. According to American Cancer Society, in 2020, there were 60,530 new cases of all kinds of leukemia which witnessed 23,100 deaths. Acute myeloid leukemia being the most prevalent accounted for 19,940 cases in US. The cancer burden in Europe is estimated to have risen to 2.7 million new cases and 1.3 million deaths in Europe as per the Joint Research Centre in European Union. Therefore, it is expected that the rising cases of leukemia and cancer may pave a way of growth for leukapheresis.

Side Effects of Leukapheresis may restrain the Growth

Like any other medical treatment, leukapheresis also have some risks and side effects which may decline its growth. Hypocalcemia, anemia, local or systematic infections may occur among the patients. Hypocalcemia is an irregular drop of calcium from the body when white blood cells are extracted. The lack of calcium in the body may cause numbness, muscle spasms, etc. Anaemia can also occur due to low count of red blood cells or platelets which may happen during the process. Although, in most of the cases, the effect of anaemia is mild. Local or systematic infections, redness and bruising at the vein puncture may also happen. All these side effects can cause the patients to decline the treatment if it is not very important.

Alternative Technologies may Cause Hindrance in Market Boost

As per the research article by pnas.org, clinical leukapheresis can concentrate mononuclear cells from almost the entire blood volume, but such large numbers and cell concentrations are incompatible with such technology. Therefore, an ultra-high throughput microfluidic chip, CTC-iChip rapidly sorts through an entire leukapheresis product of over 6 billion nucleated cells, increasing the CTC isolation capacity by two orders of magnitude. CTC based liquid biopsies provide cancer diagnostics, treatment selection, and response monitoring. Therefore, these factors may cause restrain to the leukapheresis market during the forecast period.

Competitive Landscape

Prominent players in the market include Caltag Medsystems Limited (UK), BioIVT (US), Asahi Kasei Medical Co. Ltd. (Japan), Terumo BCT, Inc. (US), MEDICA S.p.A (Italy), StemExpress, LLC (US), AllCells, LLC (US), Charles River Laboratories (US), Lonza Group AG (Switzerland), Macopharma SA (France), PuriBlood Medical Co. Ltd. (Taiwan), Miltenyi Biotec (Germany), ZenBio (US), Discovery Life Sciences (US), Intelligent Tissue Group (US), Haemonetics Corporation (US), etc.

AllCells, LLC, a leading provider of prmary cells supporting biomedical research announced in September 2020 about the addition of Cyropreserved Leukppaks to their extensive product portfolio. The primary cells are of high quality due to on-site facilities. These cells are cryopreserved using GE Healthcares GMP-compliant VIA freeze quad controlled rate freezer which is capable of consistently high post recovery and viability. Cryopreserved cells are flexible and thus, experiments on them can be done as per the schedule without waiting on delivery of fresh cells.

GET THE TABLE OF CONTENT OF THE REPORT

Novartis in October 2020 announced the authorization from Japans Ministry of Health, labour and Welfare for a site for manufacturing of commercial CAR-T cell therapy for patients in Japan. The commercial is the first to get approval in Asia. The companys aim is to being treatment closer to patients. Kymriah is the first ever FDA approved CAR-T cell therapy, and the first ever CAR-T to be approved in two distinct indications. Kymriah is currently approved for the treatment of pediatric and young adults of acute lymhoblastic leukemia.

Haemonetics Corporation, Boston based company have made an agreement to sell its Fajardo, Puerto Rico manufacturing operations to filter GVS. The company will retain all intellectual property rights to its proprietary blood filters which are currently manufactured at their Fajardo facility. The company has offered exclusive rights to manufacture and supply the blood filters. Thus, Fajardo facility will become GVS employees.

Regional Outlook

The major contributors towards the growth of leukapheresis include, increasing incidences of leukemia, growing demand for leukapheresis procedures, research applications, growing demand for leukopaks for research applications, etc.

North America is expected to hold the dominating share owing to rise in geriatric population, increasing cases of leukemia. According to Leukemia and Lymphoma Society, approximately every 3 minutes, one person is diagnosed with leukemia in US and in 9 minutes someone dies. According to American Cancer Society, 60,530 new cases of all kinds of leukemia were diagnosed in 2020 which witnessed 23,100 deaths. Acute myeloid leukemia is the most prevalent and accounted for 19,940 cases in US. North Ameirca is one of the leading countries to record deaths due to cancer and leukemia. Furthermore, research and development and new technological advancements are another factor for the market growth.

European region is also expected to have a significant growth during the forecast period 2021-2031. The acute promyelocytic leukemia which is a rare disease also accounted for 2.5 per million person in Italy, 1.39 per million in Spain, 0.54 per million in Great Britain, 0.4 per million in France according to frontiers.org. Growing AML cases are also the concerning topic, it is expected that the cases will increase by 17% by 2027, therefore increasing the growth of its treatment options. All these factors offer a contribution towards the growth of increasing leukapheresis market.

In Asia, China and Pakistan account for 36.2% and 43.5% in AML cases. Increasing medical infrastructure, emerging technologies, increasing trials and investments due to rising geriatric population, and cases of leukemia is paving the way for market growth. As per Globocan, over 20,000 new cases of childhood blood cancer are detected in India of which almost 15,000 cases are of leukemia. China is expected to witness increase over 14,000 cases of acute lymphocytic leukemia by 2029, therefore, rising incidences are projected to grow the adoption of leukapheresis.

Segmentation

Based on Type

Based on Application

Based on End user

Based on Region

Key Questions Answered

GET A DISCOUNT ON THE REPORT

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact Us:

Rohit BhiseyHead Internet MarketingTel: +1-415-520-1050Website:https://www.tmrresearch.com/

Originally posted here:
Leukapheresis Market Dynamic Demand and Drives with Forecast to 2031 - Digital Journal

Posted in Cell Therapy | Comments Off on Leukapheresis Market Dynamic Demand and Drives with Forecast to 2031 – Digital Journal

Drugs Targeting Mitochondria Developed For Leukemia Combination Therapy – Technology Networks

Posted: July 3, 2022 at 2:02 am

Researchers from Rice University and the University of Texas MD Anderson Cancer Center have discovered potential new drugs that work in concert with other drugs to deliver a deadly one-two punch to leukemia.

The potential drugs are still years away from being tested in cancer patients, but arecently published studyin the journalLeukemiahighlights their promise and the innovative methods that led to their discovery.

In previous studies, the research groups of Rice biochemistNatasha Kirienkoand MD Anderson physician-scientistMarina Konoplevascreened some 45,000 small-molecule compounds to find a few that targeted mitochondria. In the new study, they chose eight of the most promising compounds, identified between five and 30 closely related analogs for each and conducted tens of thousands of tests to systematically determine how toxic each analog was toleukemiacells, both when administered individually or in combination with existing chemotherapy drugs likedoxorubicin.

One of the big challenges was to establish optimal conditions and doses for testing on both cancer cells and healthy cells, said study lead authorSvetlana Panina, a researcher at the University of Texas at Austin who conducted the research during her postdoctoral studies at Rice. The results from our previously published cytotoxicity assay were helpful, but very little is known about these small-molecule compounds. None of them had been thoroughly described in other studies, and we had to essentially start from scratch to determine how much to use, what they do in cells, everything. All the doses and treatment conditions had to be adjusted by multiple preliminary experiments.

In prior work, Kirienkos lab had shown the eight compounds targeted energy-producing machinery inside cells called mitochondria. Dozens to thousands of mitochondria are at work every minute in every living cell, and like all machines, they wear out with use. The eight compounds inducemitophagy, the housekeeping routine cells use to decommission and recycle mitochondria that are past their prime.

During times of extreme stress, cells can temporarily forgo mitophagy to get an emergency energy boost. Cancer is notorious for hijacking these sorts of programs to fuel pathological growth. For example, previous research has shown leukemia cells have far more damaged mitochondria than healthy cells and are also more sensitive to mitochondrial damage than healthy cells.

Kirienko and Konopleva reasoned that mitophagy-inducing drugs might weaken leukemia cells and make them more susceptible to chemotherapy.

We hypothesized that if they activate mitophagy, they may be particularly toxic to leukemia cells, said Kirienko, the corresponding author of the new study. And indeed, we found that six of the eight small-molecule compounds were deadly to leukemia cells. We then wanted to study them more in depth. So we looked at closely related molecules, and we looked at combinations.

When two or more drugs are given in combination, researchers can also administer them individually and compare the effectiveness of each regimen.

There is a number called synergy coefficient that quantifies interactions between drugs, Kirienko said. If the coefficient is negative, the drugs are antagonistic and work against one another. Zero means no effect, and positive numbers indicate positive interactions. Anything above 10 is considered synergistic.

For example, one currently prescribed drug combination for leukemia doxorubicin and cytarabine has a synergy coefficient of 13, Kirienko said. The teams experiments showed several mitophagy-inducing compounds were significantly more synergistic with doxorubicin. The most synergistic, a compound called PS127B, had a coefficient of 29.

The point of synergy is that there are concentrations, or dosages, where a single drug doesn't kill, Kirienko said. There is no death of healthy cells or cancer cells. But administering those same concentrations in combination can kill a considerable amount of cancer cells and still not affect healthy cells.

The team started by testing the toxicity of its mitophagy-inducing compounds and combinations against acute myeloid leukemia (AML) cells, the most commonly diagnosed form of the disease. They then tested the six most effective AML-killing compounds against other forms of leukemia and found five were also effective at killing acute lymphoblastic leukemia (ALL) cells and chronic myelogenous leukemia (CML) cells. Control studies found all the mitophagy-inducing drugs caused far less harm to healthy cells.

In their final experiments, the researchers tested one of the most effective mitochondria-targeting compounds, PS127E, using a cutting-edge technique called apatient-derived xenograft(PDX) model. In PDX, also referred to as a mouse clinical trial, mice are implanted with cancer cells from a leukemia patient. Once the cells grow, the mouse is exposed to a drug or combination of drugs as a closer-than-cells test of the treatments effect. PDX tests on one compound, PS127E, showed it was effective at killing AML cells in mice.

Although this is very promising, were still some distance from having a new treatment we can use in the clinic, Kirienko said. We still have a lot to discover. For example, we need to better understand how the drugs work in cells. We need to refine the dose we think would be best, and perhaps most importantly, we need to test on a wide variety of AML cancers. AML has a lot of variations, and we need to know which patients are most likely to benefit from this treatment and which are not. Only after weve done that work, which may take a few years, would we be able to start testing in humans.

Reference:Panina SB, Pei J, Baran N, et al. Novel mitochondria-targeting compounds selectively kill human leukemia cells. Leukemia. 2022:1-13. doi: 10.1038/s41375-022-01614-0

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original here:
Drugs Targeting Mitochondria Developed For Leukemia Combination Therapy - Technology Networks

Posted in Cell Therapy | Comments Off on Drugs Targeting Mitochondria Developed For Leukemia Combination Therapy – Technology Networks

Dendritic Cell Therapy Vaccine Market is Growing Rapidly with Recent Demand, Trends, Development, Revenue Analysis and Forecast to 2027 Designer…

Posted: July 3, 2022 at 2:02 am

Dendritic cell therapy vaccine market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to grow at a CAGR of 20.10% in the above-mentioned forecast period. In this forecasted period dendritic cell therapy vaccines has emerged as a new growth limit for the companies involved in the research and development of drugs for the treatment of cancer.

While designing a reliable Global Dendritic Cell Therapy Vaccine Market market report, absolute industry insight, talent solutions, practical solutions and use of technology are merged together very well to advance user experience. Companies can accomplish an effectual business growth if they adopt market research report like this market report which seems to be very vital in this rapidly changing marketplace. The report brings to notice many aspects regarding HEALTHCARE industry and market. These are mainly covered with market definition, market segmentation, competitive analysis and research methodology as major topics of the winningGlobal Dendritic Cell Therapy Vaccine Marketreport. It explains market drivers and market restraints in detail which aids businesses in guessing about reducing or increasing the production of specific product.

Download Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dendritic-cell-therapy-vaccine-market&kb

The significantGlobal Dendritic Cell Therapy Vaccine Marketmarket research report looks at the key aspects of the market including its market improvement, development, position and others. It highlights the global key manufacturers and analyzes the market competition landscape. The industry inquiries in this report provide an examination and data as specified by classes. What is more, this report conducts analysis on the sales (consumption) of market, focuses on the top players to assess their sales, price, revenue and market share with volume and value for each region.Global Dendritic Cell Therapy Vaccine Marketreport also comprises of a bottomless knowledge on market definition, market drivers and market restraints, classifications, applications, and engagements.

TopCompaniesin Global Dendritic Cell Therapy Vaccine Market Report:

3M, Batavia Biosciences B.V, Dendreon Pharmaceuticals LLC, Merck KGaA, Glaxo SmithKline plc, Northwest Biotherapeutics, Inc, Tella, Inc, JW CreaGene, Immunocellular Therapeutics Inc, Argos Therapeutics, Bellicum Pharceuticals, Inc, Elios Therapeutics, Kiromic BioPharma, Healthcare

Feel Free To Ask Question Before Purchasing The Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-dendritic-cell-therapy-vaccine-market&kb

Regional Analysis

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The persuasive Global Dendritic Cell Therapy Vaccine Market marketing report provides top to bottom examination of the market as far as income and developing business sector is concerned. This business report displays systemic company profiles which illustrate how the moves of several key players and brands are driving the market. It also covers predictions regarding reasonable arrangement of uncertainties and latest techniques. The report also performs study on the market drivers and market restraints which are derived from SWOT analysis. The large scaleGlobal Dendritic Cell Therapy Vaccine Marketmarket report considers wide scope that takes into account market scenarios, comparative pricing between major players, expenditure and profit of the specified market regions.

Under the topic of market segmentation, research and analysis is carried out based on application, vertical, deployment model, end user, and geography. Besides, competitive analysis assists to get ideas about the strategies of key players in the market via theGlobal Dendritic Cell Therapy Vaccine Marketmarket document. Few of these strategies can be listed as; new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to broaden their footprints in the HEALTHCARE industry. The market share of key competitors on worldwide level is studied where main regions such as Europe, North America, Asia Pacific and South America are tackled in the universalGlobal Dendritic Cell Therapy Vaccine Marketmarket survey report.

Highlights of TOC: Global Global Dendritic Cell Therapy Vaccine Market Market

1 Global Global Dendritic Cell Therapy Vaccine Market Market Overview

2 Global Global Dendritic Cell Therapy Vaccine Market Market Competitions by Manufacturers

3 Global Global Dendritic Cell Therapy Vaccine Market Capacity, Production, Revenue (Value) by Region (2022-2029

4 Global Global Dendritic Cell Therapy Vaccine Market Supply (Production), Consumption, Export, Import by Region (2022-2029)

5 Global Global Dendritic Cell Therapy Vaccine Market Production, Revenue (Value), Price Trend by Type

6 Global Global Dendritic Cell Therapy Vaccine Market Market Analysis by Application

7 Global Global Dendritic Cell Therapy Vaccine Market Manufacturers Profiles/Analysis

8 Global Dendritic Cell Therapy Vaccine Market Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Global Dendritic Cell Therapy Vaccine Market Market Forecast (2022-2029)

13 Research Findings and Conclusion

14 Appendix

Request for TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-dendritic-cell-therapy-vaccine-market&kb

Goals and objectives of the Global Dendritic Cell Therapy Vaccine Market Market Study

This Global Dendritic Cell Therapy Vaccine Market Market Research/analysis Report Focus on following important aspects:

Key questions answered in the report:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-dendritic-cell-therapy-vaccine-market?kb

Related Reports:

https://www.databridgemarketresearch.com/reports/global-meningococcal-disease-treatment-market

https://www.databridgemarketresearch.com/reports/global-evans-syndrome-market

https://www.databridgemarketresearch.com/reports/global-ocular-lymphoma-treatment-market

https://www.databridgemarketresearch.com/reports/global-seasonal-affective-disorder-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Originally posted here:
Dendritic Cell Therapy Vaccine Market is Growing Rapidly with Recent Demand, Trends, Development, Revenue Analysis and Forecast to 2027 Designer...

Posted in Cell Therapy | Comments Off on Dendritic Cell Therapy Vaccine Market is Growing Rapidly with Recent Demand, Trends, Development, Revenue Analysis and Forecast to 2027 Designer…

Sickle cell stroke: Causes, symptoms, and treatment – Medical News Today

Posted: July 3, 2022 at 2:02 am

Sickle cell disease is a condition that affects the red blood cells. It can lead to other complications, such as stroke.

Sickle cell disease (SCD) is a condition where a persons red blood cells are misshapen or sickle-shaped. According to the American Stroke Association (ASA), SCD affects 1 in 2,400 children and 1 in 400 Black children.

A stroke occurs when there is a blockage to the brains blood supply, such as blood clotting in the blood vessels or bleeding around the brain. Both situations are more likely to happen to a person with SCD.

This article looks at the cause of stroke in SCD, how doctors diagnose and treat it, and how to reduce the risk.

For a person with SCD, their misshapen red blood cells can cause a blockage within the blood vessels. If this blockage stops blood from getting to the brain, it can cause a stroke.

Bleeding is also a complication of SCD. According to a 2020 study, bleeding in patients with SCD includes neurological, renal, and ocular bleeding complications. Neurological bleeding on or around the brain could lead to a hemorrhagic stroke.

Learn more about SCD here.

There are two main types of sickle cell stroke:

Ischemic stroke: This type of stroke happens when misshapen red blood cells block a persons blood vessels. According to a 2021 study, ischemic stroke is common in children aged 210 with SCD. The same study says incidents tend to lower between the ages of 2029 but peak again at 35.

Intracranial hemorrhage: This type of stroke is caused by bleeding in or around a persons brain. Adults aged 2030 are the most likely to experience a hemorrhagic stroke, but it is not uncommon in children. The rupture of an aneurysm commonly causes cerebral hemorrhage in people with SCD.

Learn more about ischemic stroke here.

According to the ASA, another common type of stroke seen in children with SCD is the silent stroke. It can occur in up to 39% of children before the age of 18. Doctors can detect signs of a silent stroke on an MRI scan of the brain, but there are no other outward signs. Silent strokes can cause problems with:

They are also a risk factor for future strokes.

Ischemic and hemorrhagic stroke share similar symptoms, but the time of onset sometimes differs.

The symptoms of ischemic stroke tend to appear suddenly. They include:

There may be additional symptoms in women, including:

The symptoms of intracranial hemorrhage can appear suddenly or take time to appear over a few days or weeks as pressure on the brain increases. They include:

Learn what to do if someone is having a stroke here.

If doctors suspect a stroke, they will do an initial assessment to look for typical symptoms. This can include:

A person with a suspected stroke should have a brain scan within an hour of arriving at the hospital. Doctors may use the following methods to determine whether a person is having an ischemic or hemorrhagic stroke: a computerized tomography (CT) scan or a magnetic resonance imaging (MRI) scan.

The following techniques may help determine the location, type, and cause of stroke and to rule out other conditions:

If doctors diagnose stroke in a person with SCD, they will recommend an urgent blood transfusion.

If the stroke is ischemic, a person may also receive thrombolytic medication. Doctors use this medication to break up blood clots and restore blood flow to the brain.

A person experiencing an ischemic stroke may also receive blood-thinning medication, such as aspirin or warfarin.

To treat hemorrhagic stroke resulting from a ruptured aneurysm, a person may have an open craniotomy. In this procedure, a surgeon opens a portion of the skull and uses a metal clip to stop blood loss from the aneurysm.

A person may receive additional medication to help with conditions that can lead to a stroke, such as high blood pressure or diabetes.

According to a 2015 study, routine transcranial Doppler screenings along with regular blood transfusion therapy can decrease the prevalence of overt stroke in children from 11% to 1%.

A 2019 study found that hydroxyurea, a medication taken orally, is a safe and cost-effective option for reducing the risk of silent stroke in children. However, further research is needed to confirm its effectiveness.

Although women with SCD can have a healthy pregnancy, they will need to speak with a doctor as some sickle cell disease medications may harm the baby.

General advice about reducing stroke risk includes:

According to the Centers for Disease Control and Prevention (CDC), a person with SCD must go to an emergency room if they experience any of the following:

A person should contact a doctor if they experience pain anywhere in the body that will not go away with treatment or sudden vision problems.

A person with SCD has an increased risk of stroke. Stroke can happen when sickle-shaped red blood cells clog an artery or when there is bleeding in or around the brain.

Doctors can identify a stroke using an MRI or CT scan. They may use surgical procedures or medication to treat the stroke.

A person with SCD can reduce their risk of stroke by having regular blood transfusions and transcranial Doppler screenings. Taking prescribed medications and adopting healthy lifestyle habits may also help prevent stroke.

View post:
Sickle cell stroke: Causes, symptoms, and treatment - Medical News Today

Posted in Cell Therapy | Comments Off on Sickle cell stroke: Causes, symptoms, and treatment – Medical News Today

How to live forever – Financial Times

Posted: July 3, 2022 at 2:01 am

This is an audio transcript of the FT Weekend podcast episode: How to live forever

AdvertisementIts summer. And you know what that means? Its time for a Plymouth Gin and tonic. So grab yourself a glass and some ice. Start with a pour of Plymouth gin, which is distilled using a blend of seven botanicals. Add in some tonic, then finish with a slice of orange. Now that is the perfect gin and tonic. Plymouth Gin distilled with care and craft in England since 1793.

Lilah RaptopoulosHello FT Weekend listeners, its Lilah. Im away on vacation this week so weve reached into the vault to bring you one of our favourite episodes. My team and I talk about this episode a lot. Its about living forever and the ethics of radical life extension. Its also about defying death on this outrageous family summer vacation, which feels relevant for the season. One quick note: this episode first published in November. So in the beginning, when I say last year, I mean March of 2020. Okay, enjoy the show.

Did I ever tell you about the time Ira Glass almost gave me coronavirus? It was the last day of going about our normal lives in March of 2020, and everything was starting to shut down and my office was closing, so I packed up my laptop and my keyboard and some of my notebooks into these kind of unwieldy tote bags and I slung them over my shoulder and headed home. But my last stop was this one final interview with the iconic radio host in the studios of This American Life. So Ira and I sat together in the small audio booth for an hour, and we talked about the art of storytelling, and then I left. The next day his assistant emailed me to say that I might have coronavirus because Ira might have coronavirus because he had shaken hands with someone who had coronavirus. And I remember thinking, this cannot be how I go. And that was my first brush with mortality during the pandemic and the first of many. For the next few months, mortality and I became friends. We, like, encountered each other very regularly, going to the grocery store, passing a neighbour in the hallway, taking a walk. We all encountered it, all the time. There are some people who come face to face with death early because theyve had loved ones get sick and pass. And it happens more often to us as we get older. But these past 18 months, its been different. We have a new relationship with death. Weve had to face it either as a reality or as a real possibility.

[MUSIC PLAYING]

Lilah RaptopoulosThis is FT Weekend, the podcast. Im Lilah Raptopoulous. This weekend, were thinking about mortality. Do we look death in the face or do we avoid it altogether? Were going to the extreme ends. One of the worlds top climbers defies death by scaling treacherous mountains with his kids. And FT science writer Anjana Ahuja takes us through the science of living for hundreds of years.

[CLIP PLAYING]

Leo HouldingWhat did you do today, Jackson?

Jackson HouldingWe climbed up the Pingora Peak.

Leo HouldingWhich ones that? You point to it.

Jackson HouldingThat one.

Lilah RaptopoulosThats Leo Houlding, an outdoor adventurer and a guest writer for FT weekend, chatting with his four-year-old son, Jackson.

[CLIP PLAYING]

Leo HouldingWas it hard?

Jackson HouldingUmm, not very, but a bit.

Leo HouldingWas it were you scared at all?

Jackson HouldingNo.

Lilah RaptopoulosLeo recently took his family on a vacation that would leave most of us fearing for our lives. Thats them climbing up Pingora Peak, a mountain described by the first Europeans who saw it as impossible. It was a 14-day trek deep in Wind River Country in the wilderness of Wyoming. He and his wife, Jessica, took their two kids scrambling up isolated technical terrain. Theyre four and eight. Heres Leo with his daughter, Freya, climbing Wolfs Head, a 12,000-foot summit that would be hard for most adults.

[CLIP PLAYING]

Leo HouldingWhats happening, Freya?

Freya HouldingAh, well, Ive just gone up that ridge and Im, whoo! That ridge.

Leo HouldingAwesome. [Freya making sounds while climbing] There goes Freya, heading up that east ridge of the Wolfs Head. Pretty epic. One of the more epic features youre ever likely to see anywhere in the world.

Lilah RaptopoulosOn this trip, there was no cell service. They slept in tents and they brought all their food. Some of the climbing was almost vertical roped climbing and full harnesses. Leo talks about all of this in his piece, which Ive linked to in the show notes, but it sounded so outrageous that I wanted to talk to him about it.

Leo HouldingI think discomfort is underrated and our lives are so comfortable these days. Were all kind of obsessed with making everything as comfortable as possible, whereas actually a good dose of discomfort just makes you appreciate a little bit of comfort so much more.

Lilah RaptopoulosIt should be said that Leo is sort of a climbing celebrity. Hes considered one of the best in the world. You may have seen him. Hes been in documentaries like The Wildest Dream, an Imax film that documents a climb up Everest. And hes been on TV shows like Top Gear. Hes been to Antarctica twice to climb some of the most secluded mountains in the world. So it isnt just that he wants to torture his kids. He believes in this stuff for himself, too. So off they went into the wilderness, the whole family, and two unexpected hired hands.

Leo HouldingThe problem is to do that as a family of four, you need quite a lot of stuff. Aside from the climbing gear, you need all the camping gear, sleeping gear, cooking gear and, most of all, you need food for 14 days. Total was about 100 kilos of equipment. And thats where the llamas came in. (Laughter)

Lilah Raptopoulos(Laughter) Right. Okay. So in your story, youre talking about your van getting stuck and your kids being kind of like unsure about it and youre waiting for someone to help you out. And then this groan comes from the trailer behind you.

Leo HouldingNot many people know that llama trekking is a thing in the western states. There are a couple of outfitters who rent you llamas unguided. Theyre extremely easy animals to look after, unlike horses, which, you know, you kind of have to know stuff to handle horses.

Lilah RaptopoulosSo Leo, his wife, two kids, two llamas, 14 days worth of food and gear. They avoid a moose almost immediately as they get into the backwoods. And at this point, theyre going upwards, but not climbing just yet. On the walk to their camping spot, they meet a hiker who shows them an edible mushroom the size of a football. So they take that with them. And then when they set up camp, Leos wife, Jessica, casts her fishing rod out and immediately pulls back a perfect fish. Like in the movies.

At that stage, what were you thinking? Were you thinking, okay, were good. This is going to be an easy trip?

Leo HouldingI knew it wasnt going to be an easy trip because going into the backcountry is never easy. In fact, its very hard, but its simple. You know, you dont have all the complications of modern life. Its much more about shelter and food and looking after each other. I mean, we went into the Wind Rivers with a couple of objectives in mind, some big cliffs. But for most people that go there, they go there simply to experience the wilderness. Thats something that I would recommend to absolutely everyone.

Lilah RaptopoulosBut Leo and his family arent everyone. Jessica is also an experienced mountain climber, so on that third day, they take their kids out to climb some serious, bare-faced rocks.

Leo HouldingWe did this peak called Pingora, the east ledges of Pingora, which is Jacksons first big climb where he didnt get carried. And I mean, it is a big climb. Its 1,000 feet of climbing, but the face is 2,000 feet high. You kind of come in from the side. So its, its incredibly spectacular.

Lilah RaptopoulosThe following day, Leo takes Freya on a climb thats too hard for Jackson, so they go with one of his climbing buddies.

Leo HouldingIts definitely one of the best kind of easier climbs in North America, if not the world. Its this knife-edge ridge, you know, no more than a metre wide with pretty much 300m drops on both sides, outrageously exposed. Its quite complicated terrain. You have to squirm through chimneys and you have to rappel a bit and you have to go sideways. Going sideways in climbing is actually more difficult to protect than going straight up, and watching my little girl, she got scared, you know. Of course she got scared. But she faced her fear, she controlled her breathing and she absolutely loved it. She was just grinning from ear to ear the whole day.

Lilah RaptopoulosYeah, I have to say, as you tell the story, my heart is beating fast. I imagine that, like a lot of it. And tell me if Im wrong, that a lot of it is just deciding kind of not to be scared.

Leo HouldingThats a big part of it for sure. You know, kids, whatever you introduce them to is normal for them. So Jackson, whos only five, he was only four this summer when when we did some big climbs out in America. Hes just picking his nose, eating his sweets, looking at the birds, wittering away like any other four-year-old would in any other situation. Freya is extremely confident. Shes grown up in the mountains so shes way better than most adults in that terrain. In fact, we actually overtook a couple of adult teams and they were polite about it. But it must have been a little disheartening seeing a cute little eight-year-old skipping past you (laughter) on your big adventure.

Lilah RaptopoulosAll along, Leo had planned to go on an even more serious climb right at the end of their two weeks. Just him and his climbing partner. Theyre gone for just 24 hours. And when they get back nursing cramps and muscle spasms, they find out that the rest of his family had to fend off a bear. Did I not mention? The story also includes a bear.

Leo HouldingShe tried the old banging pans together to scare it off. She did have a kind of bear spray and a hiking pole, but it was snuffling around for, you know, a few hours through the night. And then she realised there was still some food in the pots, in one of these stuff sacks. So she gingerly pushed it out from underneath the tent and ironically, the noise of that scared it off.

Lilah RaptopoulosIf you have kids at this point, you might be asking yourself, is this a little too dangerous? Why is this guy putting his kids at risk? Going into the backcountry with two little kids is one thing, but treacherous climbs, foraged food, bears?

Leo HouldingI mean, theres no question that going into the mountains, going into the backcountry is dangerous. But sometimes people think of me as a professional climber, as an adventurer, as a risk-taker. But the truth is, its very much about risk management. Its about reducing the risks as much as possible. Any idiot can roll the dice a couple of times and get away with it. But when you do it professionally and you do high-risk stuff all the time, you have to do it with a very high degree of safety. But, you know, risk is an inherent part of all life, not just lives of adventure and life in the mountains. You kind of have to accept risk in life to be able to go out and make the most of it.

Lilah RaptopoulosBut Leo says thats the point.

Leo HouldingYou know, we had a couple of pretty serious storms and there was a lot of tears and screaming, as there is in many situations with kids. But actually, sometimes its the, its the low points, its the negative experiences which are the most memorable and most formative. Now, when you get to the top of the mountain, its all smiles and high fives and sunshine. Thats great. But when youre being pelted by hail, thats kind of leaving bruises. And, you know, my wife and I were literally stooped over the kids protecting them from this vicious hail storm. And thats when they learn, as we do, that, you know, you can survive, you can endure, you can push on through, dont give up. And you just have to kind of stay on top of the situation. And then when the sun does come out, you can dry off and live to fight another day.

[MUSIC PLAYING]

Lilah RaptopoulosAnd from looking death in the eye to trying to delay it forever. If you had the chance to undergo a therapy that would let you live for 200 years in your prime body, would you do it? Im talking 200 years in the body of a 35-year-old. Not just a longer life, but a longer life thats actually good. There are scientists working hard on making that possible right now, thanks in part to funding from billionaires like Jeff Bezos. But if Bezoss space launch was criticised for wasting money, how do we feel about his quest for eternal life? Should we consider it urgent medical research? Or is this just rich mans folly? Do we really want a hacker biology to live to 200? Think about it.

[MUSIC PLAYING]

Anjana AhujaYou know, if a woman could reset her biology and have the biology of a, you know, perpetually of a 30-year-old, then what happens to the concept of generations? Are we all going to be living you know, when we talk about multigenerational households, are we talking about instead of the three at the moment, maybe four, five, six?

Lilah RaptopoulosThats Anjana Ahuja, a contributing science writer for the FT. Anjana recently wrote the cover story for Life & Arts on this radical idea. It was called, Can we defeat death? And it asks just that. Can we actually live for hundreds of years or forever? And yeah, thats a real headline from a real newspaper, not a sci-fi novel, written by a real, distinguished journalist who actually has a PhD in space physics. So heres where we are. We arent close yet to making humans age in reverse. But scientists have been able to de-age cells in living organisms. There are mice that go blind from ageing. And we can manipulate their genes so that they can see again. Were close enough to a Benjamin Button situation that philosophers are now publishing books about the morality of extending the human lifespan.

So I cant stop thinking about your piece. (Laughter) Im just like, yeah, and Im wondering, like, where this started for you. Where did you start reporting it?

Anjana AhujaBack in September, I wrote a column about Altos Labs. I found out that it was being set up, it was being funded by Jeff Bezos. And to me, it seemed like a really serious outfit in terms of the money that was going into it, the people they were recruiting. And Ive always thought this, that actually somebody, sooner or later, is going to look at ageing as a technological problem because there is so much research into kind of interfering, trying to hack the ageing process.

Lilah RaptopoulosAltos is a Silicon Valley start-up and Anjana says it expands on the work of Shinya Yamanaka, a Nobel Prize-winning physiologist who heads Altoss scientific board. In 2006, Yamanaka made a discovery that some people consider even more important than the discovery of the DNAs double helix.

News clipThe Nobel Assembly at Karolinska Institute has today decided to award the Nobel Prize in physiology or medicine 2012 to Shinya Yamanaka.

Lilah RaptopoulosHis research showed that if you take an adult mouse cell and bathed in a mixture of four proteins, you can reset that cells age back to its embryonic state. In 2007, he proved that it could be done with human skin cells. Let me say that again. If you dunk individual cells in this particular cocktail of proteins, you can make those cells not just stop ageing. You can make them younger. And we, of course, are made entirely of cells.

Im curious what, like, the practical implications would be of these findings? Like, would it be just that individual parts of your body, those cells, could kind of Benjamin Button themselves backwards and yet you still would look old? Like, is there is there a way to sort of make the entire body young? Thats a very dumb question. But is there a way to make the whole body younger?

Anjana AhujaNo, its not a dumb question at all. I think thats really what these billionaires are hoping for, isnt it, to kind of freeze themselves in some kind of eternally youthful state? I think thats a very good question. The key is how you translate from individual cells up to whole organisms.

Lilah RaptopoulosThe name for what happens when you bathe cells in the Yamanaka Factor proteins is cellular reprogramming. Scientists try to reprogramme the cells of an entire body on mice, but when they did, the mice grew these horrible malignant tumours. Anjana put it like this. She said once you bring the cells back to their embryonic state, they lose their life plan. They dont know what to do next, so they grow into cancers. But there are companies right now working to see if you can apply these factors incrementally to de-age cells as far as you can without them developing cancer and then to do it again.

Anjana AhujaI suspect people will be quicker to apply it to individual organs first, individual tissues. You know, when you think about the number of people whose organs just wear out, they need transplants. So that might be an option.

Lilah RaptopoulosThis research, it isnt the only path to reverse ageing. A California scientist has been giving a small group of middle-aged men this cocktail of drugs that includes diabetes medication. Its made their thymus glands, which is a key part of the immune system, younger by two-and-a-half years. David Sinclair, a Harvard geneticist and one of the biggest names in anti-ageing. Hes doing a lot to experiment on his own body, including only eating one or two meals a day to put his body into survival mode. But Yamanakas discovery and where its going, thats whats really changing the game for longevity research. And to tell you the truth, thinking about it really pushed me on my assumptions about scientific progress, especially progress driven by Jeff Bezos.

These stories can look a little like the stories of men with too much money in Silicon Valley (laughter) just trying to like, kind of like, still be young and cool, right? Like, kind of suspend reality and like, isnt there something, even if its hard, comforting about the fact that we understand that, like, theres a limit to our lives and we understand the arc of it and, and we all die.

Anjana AhujaYeah, I mean, why dont these billionaires put their money to solving climate change and starvation and, you know, giving us clean drinking water and that kind of thing? You know, whats really interesting to me, I think, is when you think about what healthcare is.

Lilah RaptopoulosMmhmm.

Anjana AhujaIts about postponing death.

Lilah RaptopoulosYeah.

Anjana AhujaYou know, if you say to someone, you know, if you could not have cancer, not have heart disease, not have Alzheimers, not have dementia, if you could find a therapy that did that, would you take it? And I think there would be a lot of people that would say yes.

Lilah RaptopoulosMmhmm.

Anjana AhujaAnd what the scientists are saying, well, actually, you know, ageing is the common factor in lots of these diseases.

Lilah RaptopoulosMmhmm.

Anjana AhujaSo instead of, you know, kind of waiting till Alzheimers or heart disease or diabetes hits, why dont we make an upstream intervention and stop the root cause, or one root cause, which is ageing?

Lilah RaptopoulosAt the moment, though, most people seem to be sceptical of radical life extension. Anjana quotes the survey in her piece that only four per cent of Americans recently said theyd want to live past 120. Statistically, thats pretty close to no Americans wanting to live past 120. And Anjanas right! Part of that scepticism is that we cant imagine our world without Alzheimers, cancer and heart disease because the image we have is of old age as we know it now, one that is inextricably linked to disease and frailty and loneliness. But even if we could get rid of the negative consequences of ageing, if we can have lives that arent just longer but good till the end, should we? Have we really thought this through? What about the climate crisis and overpopulation and burning through our limited resources? What about marriage? Can you stay married to one person for 150 years? How many careers should we have over 200 years? What about dictators who dont ever die? Supreme Court justices? What about the House of Lords?

Anjana AhujaWhat do you do in the judicial system? You know, what does a life sentence mean, if youre living for 150, 200 years?

Lilah RaptopoulosYeah.

Anjana AhujaAnd just this idea that kind of a lot of institutions in society are set up with finite life spans in mind.

Lilah RaptopoulosAs we ended this conversation, I held two opposing feelings at once. One is, if this discovery happened today, it would be a nightmare on a macro scale, and we are not ready for it. And the other is, if I could give someone I love whos suffering from degenerative disease a pill to stop their pain or to reverse the damage, I would in a heartbeat, no question. And to not feel that way is kind of to be against progress.

Anjana AhujaI think there are some really important issues that may well become more important in the decades ahead. I dont know how close any of this is to fruition, this work about, you know, radical life extending. Could I live to 200? I dont know. And Im not sure that I would necessarily be able to make that decision today.

Lilah RaptopoulosYeah.

Anjana AhujaI think I would want to see what state the science was in, what state the research was in, what state I was in, and what kind of life I felt I could have, how I felt psychologically about it, what my family feel about it. You know, do they want me hanging around for a hundred years (laughter)?

Lilah RaptopoulosWould the people around you also be hanging around for an extra 100 years?

Anjana AhujaExactly. You know, we are going to get horribly bored with each other. So who knows? I mean, these are really big issues, but I hope that the piece is open to debate and we should talk about these things. Theyre always good because you never know how fast science is going to progress. Yeah. And sometimes, as weve seen with, you know, gene editing and CRISPR, sometimes these things hit before weve had a chance to think about them.

Lilah RaptopoulosMmhmm.

Anjana AhujaAnd I think its always really useful for us to just take a step back and reflect on how we live, how science might change things, and on what we feel comfortable with and, and, you know, the future of our species and our society.

Lilah RaptopoulosAnjana, youve given me so much to think about and probably our listeners too. Thank you so much for being on the show.

Anjana AhujaOh, its been my pleasure, Lilah. Thank you for having me!

[MUSIC PLAYING]

Lilah RaptopoulosAnd a final thought. We may be doing some of this life extension work already. We do live in a world of optimisation. We have apps to help us meditate. Our phones count our steps. We have strange little tools we attach to the back of our necks to help our posture. My watch tells me to stand up and breathe. My friends have a bed that heats up and cools down according to their optimal body temperature. There are start-ups that make vitamins specifically for your personal constitution. This isnt just scientists in a lab testing proteins on mice. This is kind of already happening.

Tiffany DarkeSo actually, what these tools, all the good tools for longevity that are coming into the market do is they help increase your health span as opposed to your life span.

Lilah RaptopoulosThats Tiffany Darke. Shes a regular contributor to the FTs luxury magazine, How to Spend It. She just wrote a piece on what the really rich are doing now to optimise their health. And shes pretty into it.

Tiffany DarkeIm a bit of a luxury junkie. Ive always, like, appreciated fashion. And I think that the science and the thought leadership around the luxury wellness industry has sort of increased exponentially in recent years.

Lilah RaptopoulosLets be clear. Living long is a luxury. The difference between being wealthy and poor can translate to living 10 or 20 years longer or shorter. And living long well, thats an even bigger luxury. In the UK, 20 per cent of mens lives are spent in poor health, a number thats increasing. And for women, thats even higher. Its 23 per cent. But for those that can afford it, there are a lot of new options. Were going to take you through a few of them here. The first is called RoseBar. Its a destination longevity programme and its marketing offers you a pretty bold promise.

Tiffany DarkeIt says a year from now, you can be younger. So they are promising reversal of ageing.

Lilah RaptopoulosThe RoseBar programme is a year-long programme. First they run longevity diagnostics and your bloodwork to see if youre on any negative health trajectories. And if you are, they put you on antidotes, which could be plasma treatments or even stem cell manipulation. From there, they give you fitness and diet advice and monthly check-ins. And the first programme launches this month at a resort in Ibiza. Its got a hyperbaric chamber, cryotherapy and IV facilities and literal shamans. Its like buying a souped-up life coach.

Tiffany DarkeYes, yes, life coach but with lots of kind of doctors and clinicians and all the sort of fun toys that surround the longevity industry as well.

Lilah RaptopoulosThe cost is, base, 15,000.

Tiffany DarkePlus the actual residential costs, plus getting there, plus the cost of the nutraceuticals, plus all the treatments.

Lilah RaptopoulosIf thats a bit too steep for you, theres a start-up called Thriva. Its an app that sends you a blood sample kit. The cost starts around $30 and can go as high as almost $200 per test, depending on your add-ons.

Tiffany DarkeIm warning you, its totally addictive. So you download this app on to your phone and then they send you a blood test and you do your blood test every three months. And its really easy at home, pinprick in the end of your finger.

Lilah RaptopoulosThey test what your doctor does at a normal check-up: your cholesterol, kidney and liver function, testosterone, vitamin levels. But they test it way more frequently and they put the results in an app, gamified. Next are the supplements. Lima sells supplements with nine scientifically backed ingredients: D3, keratin, ashwagandha, turmeric, stuff like that, but branded to look cool. You may have heard them referred to as the supermodel supplements: four pills a day, $300 a month, and you even get a luxe copper vessel to store them in.

Tiffany DarkeTheres a lot of hocus-pocus in the supplement market and, you know, a lot of good marketing, but actually there are supplements out there that do use good, patented adaptive medicines and at the dosages that your body needs to really thrive.

Lilah RaptopoulosWhich begs the question, are these just high-tech tools reminding us to do the obvious? Eat vegetables, avoid processed foods, take your vitamins, drink water, get sleep, exercise. Its all advice thats as old as time, but its a lot easier to follow when you can afford to get real-time data. And it doesnt hurt to have a shaman reminding you on a beach in Ibiza.

[MUSIC PLAYING]

Lilah RaptopoulosThats it for this week. Youve been listening to FT Weekend, the podcast from the Financial Times. Please keep in touch, say hi, tell me what you like, what issues you want to hear us explore. You can email us at ftweekendpodcast@ft.com. Were on Twitter @FTWeekendPod and Im on Instagram and Twitter @LilahRap. Ill put some photos of Leos family adventure on my feeds and, really, reach out. We love to put listeners on the show. In our show notes, as always, are links to everything mentioned. Theres also a special discount there on an FT Weekend subscription or even an FT.com trial. Weve got the best discounts collected for you in that link, which you can also get to at ft.com/weekendpodcast. Please leave us a review and share the show on your Twitter or Instagram story or with a few friends. This really is the best way you can help support the show.

See the article here:
How to live forever - Financial Times

Posted in Wyoming Stem Cells | Comments Off on How to live forever – Financial Times

Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research | npj Breast Cancer -…

Posted: July 3, 2022 at 2:01 am

We discussed challenges to initiate and maintain researcheradvocate relationships, and proposed short- and long-term solutions (Table 1):

The first challenge is that it is not clear why patient advocates should be included in research. Sometimes researchers feel that their work is too far removed from the patient or that the patient advocate may not be able to provide anything valuable to the research. There are plenty of resources that describe the value of these relationships, but more can be done to ensure the value is demonstrated8,12,13.

In the short-term, anecdotal stories can support researchers realization of the value of working with patient advocates. Groups that require patient advocate involvement for funding, such as the Department of Defense Breast Cancer Research Program, should supply clear, public statements describing the benefit of including patient advocates in the research process. All disease-related research funding groups should encourage or require patient advocate input and involvement in grant projects, both to support writing the project plan and as part of developing the hypothesis, designing the project, and supporting dissemination of the findings. Researchers should ensure that they avoid engaging in performative advocacy (having a token advocate) through clear and frequent communication with the patient advocate. Performative advocacy is when patient advocates are included in research discussions to fulfill a requirement by simply saying a patient advocate was present, rather than listening to the patient advocates suggestions and incorporating their feedback into the study.

In the long-term, it would help to initiate a research project whose goal is to evaluate the added benefit of researchers working with patient advocates. This type of work should consider endpoints such as funding, publications, and overall satisfaction with work. Additionally, clinical endpoints may also improve and thus should be measured including translation to the clinic and engagement of diverse populations in related trials.

The second challenge is that researchers are worried about saying the wrong thing. During the panel discussions, one researcher said, its intimidating. I dont want to fail the patients. I want what Im doing to be meaningful. Some researchers fear working with a patient advocate in case they want a cure or have unrealistic expectations of how quickly (or how slowly) the research is going to move, which may feed into the researchers concern of failure. Metastatic disease is currently not curable, and many (but not all) patients will have limited time to live, and thus many researchers fear that they will say something that is insensitive given this challenging situation.

Open lines of communication are extremely important as they establish expectations from the start that everyone is learning from each other and ensure the environment is a safe space. Both groups should feel that they can ask questions they may feel like others know the answer to. They should also feel comfortable respectfully correcting others within their own areas of expertise. Our discussions noted that scientists have not historically been trained to communicate with nonscientists, but there is increasing recognition of this shortcoming, and current trainees will hopefully reap the benefits of increased attention to this matter13,14.

There is a need for training programs in which researchers learn how to work with patient advocates. This could be a workshop at a conference or annual retreat, or part of a class about communication. Conferences like the American Association for Cancer Research (AACR) Annual Meeting, the American Society for Clinical Oncology (ASCO) Annual Meeting, the San Antonio Breast Cancer Symposium (SABCS), and the Metastasis Research Society (MRS) Biennial Congress should consider including training sessions on best practices for working with patient advocates at their events.

The third challenge is that researchers do not know where to meet patient advocates. Initially, connecting with patient advocates can be challenging for researchers. It can happen through a variety of venues, though, through formal programs like those at Georgetown University8 and Huntsman Cancer Institute or informally through forums like Twitter by following #BCSM and other cancer-specific social media tags.

In the short-term, researchers should review established advocate programs to determine if they would benefit from initiating similar programs at their institutions. Georgetown University and Huntsman programs are examples where patient advocates meet regularly to support research at their respective cancer centers by providing a forum for researchers to explain their work and meet new patient advocates. Patient advocates could be invited to annual retreats to give those who do not normally work with advocates a chance to establish collaborations. Kansas University developed a researcher/patient advocate toolkit called PIVOT (Patient and Investigator Voices Organizing Together) AdvocateResearcher Working Together Toolkit15, which provides additional best practices for establishing relationships. The National Cancer Institute Specialized Program of Research Excellence (SPORE) grants are structured to bring basic research to a Phase I Trial and SPORE applications are required to include advocates.

There are scientific conferences that support patient advocate participation and interaction with researchers such as the Metastatic Breast Cancer Research Conference and AACRs ScientistSurvivor Program. Additionally, an organization run by patient advocates called Guiding Researchers and Advocates to Scientific Partnerships (GRASP) fosters patient advocate and researcher interactions through poster discussions at conferences. Conferences also benefit from facilitating opportunities for patient advocates and research scientists to have formal interactions through panel discussions and informal interactions like coffee chats or happy hours.

In the long-term, it would be beneficial to develop a national database for researchers and patient advocates to connect that includes the persons interests, location, and time commitment. Groups like GRASP have already started this type of database that includes hundreds of patient advocates and researchers. It would be helpful if this database were turned into a tool or phone app that connects researchers and patient advocates through a series of questions similar to something like match.com. Developers should work towards being inclusive of research on multiple cancer types and consider piloting the tool or app in a specific region to optimize it before opening it up nationwide.

The final challenge is that researchers do not know how to include patient advocates in research. Once a researcher has met a patient advocate, they may not know how to continue to include the patient voice in their work. It is extremely important to establish open lines of communication as groundwork for collaboration, and ensure patient advocates are appropriately compensated. Both researchers and patient advocates should establish their expectations when starting to work together. It is important to understand whether the collaboration will be a short- or long-term engagement and both parties should consider time commitments with regard to frequency of meetings as well as the length of meetings.

Ideally, researchers should begin working with patient advocates early in their career16. To support these relationships, institutions should build programs to support that connection. A few examples of success include:

Cornell Community Cancer Partnership: Cornell has developed a program that brings community members affected by, or interested in, cancer together with basic research Ph.D. students16. They have monthly seminars where graduate students give presentations in common language or community members describe their experiences living with cancer17. The program focuses on science communication and exposing trainees to the human side of cancer.

Cancer Trainee Advocate Program (CTAP): This program is a resource for how to get trainee programs started at institutions and provides a few examples. The goal is to bring patient advocates from the community together with trainees to have initial discussions about experiences with cancer and their research, respectively.

Cellular and Molecular Basis of Disease Course in the Cellular and Molecular Medicine Ph.D. Program at Johns Hopkins University: During the first year of graduate study, M.D. or Ph.D. faculty members present lectures on human diseases and often bring in a patient to share their perspective. These studentpatient interactions are described by students as a highlight of their educational experience.

There are many other examples, both at the national and local level9. Once relationships are established, researchers should create a process for maintaining collaboration. Patient advocates enjoy being involved with every step of the research process and including advocates throughout the grant writing process avoids performative advocacy. Researchers should consider patient advocates involvement in grants early in the process, not only to support the merit of the grant in the review process, but as a true partner as the grant progresses. This likely involves including them in the budget and/or as a co-author on publications, as appropriate. Having a long-term relationship supports the organic process of patient advocate involvement, which allows time for advocates to become partners in research as the project progresses. A few suggestions for long-standing collaboration are included in Table 2.

It is important for researchers to consider ways to compensate patient advocates for their time, which may include paying for service, covering travel, or inclusion in a manuscript. Researchers should discuss compensation with patient advocates but understand that there are complexities such as the impacts of receiving disability benefits. The field would benefit from more comprehensive discussions and guidance regarding compensation for patient advocates, including intricacies, appropriate amounts, where funding for advocates comes from.

In the long-term, it would help to have clearer definitions of roles for patient advocates receiving compensation or providing effort in grant applications and research projects. The National Cancer Institute (NCI) should consider explaining how advocacy fits into their NCI Comprehensive Cancer Center designation rubric to more clearly demonstrate the value these relationships bring to cancer centers. There is a potential opportunity to include patient advocates in the context of community outreach and engagement (COE). Laying out expectations of researchers working with patient advocates, as well as the purpose for the interactions, would be a great benefit to the community and improve cancer research overall.

In conclusion, our analysis identified two major barriers to research scientist working with patient advocates. The first is that research scientists do not know how to initiate the relationship and the second is that they are unsure of what the relationship should look like. For cancer researchers, we have highlighted ways to collaborate with patient advocates and outlined examples of established best practices from multiple institutions, a resource that has not been comprehensively outlined before. We hope this document will inspire new relationships and programs as we move towards ensuring the patient voice is considered along the continuum of research. While focused, our discussions were not quantitative in nature. To support implementation of programs, academic centers would likely benefit from a more quantitative description of the approach and outcomes. Future studies should collect detailed demographics and expand the group to diverse demographic groups, especially with respect to gender, age, income, and race. Ultimately, these relationships will improve cancer research and more quickly accomplish our collective goal of improving lives of those who have been diagnosed with cancer. We recommend this relationship would be incorporated as part of the infrastructure of the basic research in cancers.

See the original post:
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research | npj Breast Cancer -...

Posted in Molecular Medicine | Comments Off on Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research | npj Breast Cancer -…

Should Covid tests be free again? Thousands sign petition as cases surge in UK – NationalWorld

Posted: July 3, 2022 at 2:01 am

More than 426,000 people have signed a petition against the end of free testing kits, which has now been delivered to Downing Street

Covid rates in the UK have surged recently - due to the BA.4 and BA.5 variants - leading to campaigners calling for free tests to return.

Dr John Puntis, co-chair of Keep Our NHS Public and lead of the petition, said the recent rise of Covid cases made the petition to bring back free lateral flow tests even more relevant.

He said that although there are fewer cases of serious illness and death from Covid, there are still 3.7 million people in England classed as clinically extremely vulnerable from Covid.

He added that more than two million people in England who have had long Covid often live with the devastating effects on their quality of life and ability to work.

Dr Puntis said the petition sends a strong message to Prime Minister Boris Johnson that there is much more to be done and that living with Covid has to be a lot more than just vaccination.

It must include widespread testing, free lateral flow tests, sick pay and support for self-isolation, mask wearing in crowded indoors, flexible working, and clean air through improved ventilation systems. It is time to put public health at the heart of our response to Covid, Dr Puntis added.

Martin Michaelis, professor of molecular medicine at the University of Kent, also agreed that free testing for Covid needs to be made publicly available on a widespread basis again.

He said if the spread of Covid is to be reduced then people need to know whether they are infected and may infect others.

Without tests, nobody can know whether they carry the virus or not, he added.

Prof Michaelis said that due to the high level of pre-existing immunity - which is down to vaccinations and previous infections - many people do not experience symptoms when they are infected with Covid.

He added that even those who do have symptoms cannot know with certainty whether they have Covid or another respiratory infection.

Many people will therefore unknowingly spread Covid if they do not have an easy opportunity to test themselves, he added.

He also said that although many people have a high level of immune protection from Covid, there is a significant proportion of the population whose immune system is not working properly and who cannot protect themselves by vaccination.

These people are put at a much higher risk when the Covid levels are high in the population, said Prof Michaelis.

Since people can only avoid spreading the virus when they know that they have it, free testing is an important measure that reduces Covid spread and, in turn, the risk of future devastating Covid waves, he added.

Read more from the original source:
Should Covid tests be free again? Thousands sign petition as cases surge in UK - NationalWorld

Posted in Molecular Medicine | Comments Off on Should Covid tests be free again? Thousands sign petition as cases surge in UK – NationalWorld

Homepage | Retired State Employees Association of Louisiana (RSEA)

Posted: July 3, 2022 at 1:59 am

Association Member Benefits Advisors (AMBA) may not be a name you're familiar with, but may play an important role in your life. AMBA's services and benefits have been helping association members like you for over 65 years. Get to know AMBA's mission and how they make sure their association partners like us get the service and benefits they deserve.

Get to Know AMBA > https://blog.amba.info/the-amba-story/

#peaceofmind #memberbenefits #benefitsadvisors

Learn About AMBA > https://blog.amba.info/the-amba-story/

#peaceofmind #memberbenefits #benefitsadvisors

Researchers are exploring the possibility of people being able to regrow adult teeth by harvesting the stem cells in our teeth. What does this mean for the future of dental care and how close is the solution?

Learn More > https://blog.amba.info/stem-cells-help-replace-teeth/

Your association and AMBA offer a Dental Plan that help covers everything from routine check-ups to procedures like the cost of extractions, root canals, crowns, and more. Sign up now for the plan thats right for you at http://www.AMBAdentalvision.com or call 866-979-0497.

#dentalcare #stemcells #rootcanals

Read more here:
Homepage | Retired State Employees Association of Louisiana (RSEA)

Posted in Louisiana Stem Cells | Comments Off on Homepage | Retired State Employees Association of Louisiana (RSEA)

Page 365«..1020..364365366367..370380..»